AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15920748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling with regular foods (group 1)
Number of subjects: 75
Study 15920748 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual diet plus supplements (group 2)
Number of subjects: 75
Study 15920748 — intervention group
Group type: COMPARATOR
Intervention: Intake ad lib (group 3)
Number of subjects: 75
Study 11833023 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiGym
Number of subjects: 17
Study 11833023 — intervention group
Group type: EXPERIMENTAL
Intervention: ElasticGym
Number of subjects: 17
Study 10410790 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography in patients without neuromuscular disorders
Number of subjects: 75
Study 10410790 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography in patients with neuromuscular disorders
Number of subjects: 75
Study 10410790 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy examinees
Number of subjects: 75
Study 7749435 — intervention group
Group type: EXPERIMENTAL
Intervention: 252 mg quinacrine pellets
Number of subjects: 33
Study 7749435 — intervention group
Group type: EXPERIMENTAL
Intervention: 324 mg quinacrine pellets
Number of subjects: 33
Study 7749435 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quinacrine (previously reported)
Number of subjects: 33
Study 1703909 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-EPO at a dose of 3 x 80 U/kg body weight per week
Number of subjects: 20
Study 1703909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1703909 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-EPO
Number of subjects: 20
Study 850695 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive facilitation patterning
Number of subjects: 42
Study 850695 — intervention group
Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 42
Study 850695 — intervention group
Group type: COMPARATOR
Intervention: Target throwing
Number of subjects: 42
Study 31190494 — intervention group
Group type: EXPERIMENTAL
Intervention: Articular needling at Sifeng (EX-UE 10)
Number of subjects: 64
Study 31190494 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study 28724962 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-transcript signature
Number of subjects: 47
Study 28724962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-transcript signature
Number of subjects: 47
Study 25755034 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441
Study 25755034 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study 23863036 — intervention group
Group type: EXPERIMENTAL
Intervention: Less oxidized omega-3 oil pills
Number of subjects: 52
Study 23863036 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly oxidized omega-3 oil pills
Number of subjects: 52
Study 23863036 — intervention group
Group type: COMPARATOR
Intervention: No capsules (control group)
Number of subjects: 52
Study 21680159 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator-driven quantitative approach (visual inspection and manual labeling)
Number of subjects: 28
Study 21680159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated quantitative approach (image segmentation, voxel intensity thresholding, seed growing)
Number of subjects: 28
Study 21680159 — intervention group
Group type: COMPARATOR
Intervention: Both approaches (operator-driven and fully automated)
Number of subjects: 28
Study 18665696 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 277
Study 18665696 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Counseling (TC)
Number of subjects: 277
Study 18665696 — intervention group
Group type: COMPARATOR
Intervention: Monitoring Group (MG)
Number of subjects: 277
Study 18665696 — intervention group
Group type: EXPERIMENTAL
Intervention: NET
Number of subjects: 277
Study 18665696 — intervention group
Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 277
Study 18665696 — intervention group
Group type: EXPERIMENTAL
Intervention: NET and TC
Number of subjects: 277
Study 17067376 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (3 wards)
Number of subjects: 167
Study 17067376 — intervention group
Group type: COMPARATOR
Intervention: Control (2 wards)
Number of subjects: 167
Study 12866115 — intervention group
Group type: EXPERIMENTAL
Intervention: XeCl excimer TMLR
Number of subjects: 30
Study 12866115 — intervention group
Group type: COMPARATOR
Intervention: Optimal cardiac medication (controls)
Number of subjects: 30
Study 10831267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 76
Study 10831267 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 76
Study 9168460 — intervention group
Group type: EXPERIMENTAL
Intervention: Menhaden oil (6.26 g, n-3 fatty acids) with vitamin E (900 IU)
Number of subjects: 80
Study 9168460 — intervention group
Group type: EXPERIMENTAL
Intervention: Menhaden oil (6.26 g, n-3 fatty acids)
Number of subjects: 80
Study 9168460 — intervention group
Group type: COMPARATOR
Intervention: Menhaden oil (6.26 g, n-3 fatty acids) with placebo instead of vitamin E
Number of subjects: 80
Study 9168460 — intervention group
Group type: COMPARATOR
Intervention: Olive oil with vitamin E (900 IU)
Number of subjects: 80
Study 1550166 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline pump
Number of subjects: 725
Study 1550166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 725
Study 1550166 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 725
Study 3929308 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 32
Study 3929308 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 32
Study 30808668 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches + 18 mg/mL nicotine e‐cigarette
Number of subjects: 1809
Study 30808668 — intervention group
Group type: COMPARATOR
Intervention: 21 mg nicotine patches + nicotine free e‐cigarette
Number of subjects: 1809
Study 30808668 — intervention group
Group type: COMPARATOR
Intervention: 21 mg nicotine patches
Number of subjects: 1809
Study 29521661 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 40-mg chloroprocaine 1%
Number of subjects: 50
Study 29521661 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with sufentanil, propofol and a laryngeal mask
Number of subjects: 50
Study 27354234 — intervention group
Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 193
Study 27354234 — intervention group
Group type: COMPARATOR
Intervention: Packaged Cognitive‐Behavioral Treatment (PCBT)
Number of subjects: 193
Study 25256624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral aspherical toric IOL implantation
Number of subjects: 86
Study 25256624 — intervention group
Group type: COMPARATOR
Intervention: Bilateral aspherical control IOL implantation
Number of subjects: 86
Study 25256624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 86
Study 23075518 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo™ device treatment
Number of subjects: 358
Study 23075518 — intervention group
Group type: COMPARATOR
Intervention: Not treated with NeuroFlo™ device
Number of subjects: 358
Study 20186137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2153
Study 20186137 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2153
Study 20186137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2153
Study 17032098 — intervention group
Group type: COMPARATOR
Intervention: TLFB interview
Number of subjects: 509
Study 17032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic BMI
Number of subjects: 509
Study 17032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced BMI
Number of subjects: 509
Study 17032098 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 509
Study 12743579 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (10, 30, or 100 mg in suspension)
Number of subjects: 33
Study 12743579 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg administered as two 200-mg doses 2 hours apart)
Number of subjects: 33
Study 12743579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10659016 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty
Number of subjects: 38
Study 9295819 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 micrograms/kg, 20‐mL bolus) followed by continuous infusion (3.5 micrograms/kg/hr) for 72 hrs
Number of subjects: 10
Study 9295819 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (20‐mL bolus) followed by continuous infusion (20 mL for 30 mins)
Number of subjects: 10
Study 8441895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg o.d.)
Number of subjects: 34
Study 8441895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3729492 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 63
Study 3729492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MT)
Number of subjects: 63
Study 3729492 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (DP)
Number of subjects: 63
Study 3729492 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63
Study 31202508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen acid orodispersible tablets (Test product)
Number of subjects: 36
Study 31202508 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen acid oral tablets (Reference product)
Number of subjects: 36
Study 31202508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen S(+) and R(−) enantiomers
Number of subjects: 36
Study 29395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 20 mg/kg oral daily for 14 weeks
Number of subjects: 171
Study 29395273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 29395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 171
Study 27028371 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Number of subjects: 140
Study 27028371 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 140
Study 25148049 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg daily for 12 weeks
Number of subjects: 30
Study 25148049 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study 25148049 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 30
Study 25148049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT scans (sub-group of participants)
Number of subjects: 30
Study 22178268 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (short course, 24 hours)
Number of subjects: 130
Study 22178268 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin (usual course, 72 hours)
Number of subjects: 130
Study 20101593 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate (OCH)
Number of subjects: 0
Study 20101593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20101593 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 0
Study 18807578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of omeprazole (20 mg)
Number of subjects: 50
Study 18807578 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of omeprazole (20 mg)
Number of subjects: 50
Study 17283347 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute session of motivational counseling during hospitalization (n = 172)
Number of subjects: 341
Study 17283347 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 169)
Number of subjects: 341
Study 12823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light therapy (30 minutes of 400 lux green light treatment)
Number of subjects: 30
Study 12823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg) with morning light therapy
Number of subjects: 30
Study 12823078 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg) with placebo (deactivated negative ion generator)
Number of subjects: 30
Study 10702431 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic recombinant antithrombin
Number of subjects: 0
Study 9100603 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2; 48 micrograms/day)
Number of subjects: 5
Study 9100603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 alpha-dihydrotestosterone (DHT; 7.0 mg/day)
Number of subjects: 5
Study 9100603 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 5
Study 8448069 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha MeHA, 10 mg (as a chloride salt)
Number of subjects: 6
Study 8448069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study 3768929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day of metolazone
Number of subjects: 187
Study 3768929 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of chlorthalidone
Number of subjects: 187
Study 3768929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 3768929 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone
Number of subjects: 187
Study 3768929 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 187
Study 29970355 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based partner notification (n=95)
Number of subjects: 370
Study 29970355 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based partner notification with partner referral cards (n=84)
Number of subjects: 370
Study 29970355 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner referral cards (n=97)
Number of subjects: 370
Study 29970355 — intervention group
Group type: COMPARATOR
Intervention: Simple partner notification counseling (control; n=94)
Number of subjects: 370
Study 26524001 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-value intervention where students wrote about the personal relevance of course material
Number of subjects: 1040
Study 26524001 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1040
Study 26524001 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-value intervention
Number of subjects: 1040
Study 24706489 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 250
Study 24706489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 22228217 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-based computer simulation (n = 41)
Number of subjects: 82
Study 22228217 — intervention group
Group type: COMPARATOR
Intervention: Skill laboratories (n = 41)
Number of subjects: 82
Study 21245500 — intervention group
Group type: COMPARATOR
Intervention: Treadmill running at 3.35 m/s ± 5%
Number of subjects: 20
Study 21245500 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground running at 3.35 m/s ± 5%
Number of subjects: 20
Study 18565100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 52
Study 18565100 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 52
Study 16428156 — intervention group
Group type: COMPARATOR
Intervention: Vehicle application of 70% alcohol
Number of subjects: 114
Study 16428156 — intervention group
Group type: COMPARATOR
Intervention: 10% phenol in 70% alcohol
Number of subjects: 114
Study 16428156 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% salicylic acid gel
Number of subjects: 114
Study 12588471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cold and citrus (CD + CT)
Number of subjects: 87
Study 12588471 — intervention group
Group type: COMPARATOR
Intervention: Room temperature (RT)
Number of subjects: 87
Study 12588471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cold and citrus (CD + CT) in healthy young subjects (<60 years)
Number of subjects: 87
Study 10226719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) applied 3-4 times a year for 4 years
Number of subjects: 269
Study 10226719 — intervention group
Group type: COMPARATOR
Intervention: No professional fluoride application (Control group)
Number of subjects: 269
Study 9162365 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration and continuous drainage over 24 hours (group 2)
Number of subjects: 32
Study 9162365 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous aspiration alone (group 1)
Number of subjects: 32
Study 1907241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (thrombolytic therapy)
Number of subjects: 533
Study 1907241 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 533
Study 6809158 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stable measles vaccine; stored unreconstituted at 37 degrees C for 14 days
Number of subjects: 0
Study 6809158 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stable measles vaccine; reconstituted and stored at 25 degrees C for 48 hours and at 37 degrees C for at least four hours
Number of subjects: 0
Study 6809158 — intervention group
Group type: COMPARATOR
Intervention: Conventional measles vaccines
Number of subjects: 0
Study 30570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate double‐coated anorganic bovine bone (InduCera)
Number of subjects: 25
Study 30570584 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone (Bio‐Oss)
Number of subjects: 25
Study 28683994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone, 250 mg at anesthetic induction and 250 mg at initiation of CPB (n=44)
Number of subjects: 81
Study 28683994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=37)
Number of subjects: 81
Study 25712416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg the day before PCI and 40 mg 2-4 h before PCI)
Number of subjects: 23
Study 25712416 — intervention group
Group type: COMPARATOR
Intervention: Low-dose statins
Number of subjects: 23
Study 23811624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal block with 8 ml of 0.3% ropivacaine and 100 µg of fentanyl
Number of subjects: 48
Study 23811624 — intervention group
Group type: COMPARATOR
Intervention: Non-block (no caudal block)
Number of subjects: 48
Study 22066975 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 40) performing daily exercise with weekly load increase for 3 months
Number of subjects: 81
Study 22066975 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n = 41) wait-listed
Number of subjects: 81
Study 18271691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) with yogurt enriched by low doses of n-3 PUFA (n-3 LCD)
Number of subjects: 40
Study 18271691 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (LCD)
Number of subjects: 40
Study 16942967 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Triple P-Positive Parenting Program intervention
Number of subjects: 0
Study 16942967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study 12738506 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 16
Study 12738506 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 16
Study 10853928 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 28
Study 10853928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 28
Study 9351414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA
Number of subjects: 200
Study 9351414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA + PCB
Number of subjects: 200
Study 9351414 — intervention group
Group type: COMPARATOR
Intervention: GA without PG treatment
Number of subjects: 200
Study 9351414 — intervention group
Group type: COMPARATOR
Intervention: GA + PCB without preoperative PG
Number of subjects: 200
Study 9351414 — intervention group
Group type: COMPARATOR
Intervention: GA + PCB
Number of subjects: 200
Study 9351414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively
Number of subjects: 200
Study 8465022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 03-8799 (pimonidazole)
Number of subjects: 183
Study 8465022 — intervention group
Group type: COMPARATOR
Intervention: Control arm (radiotherapy)
Number of subjects: 183
Study 3517799 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carrying
Number of subjects: 99
Study 3517799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 30518237 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based language training
Number of subjects: 71
Study 30518237 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper/pencil language training
Number of subjects: 71
Study 30518237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral language training
Number of subjects: 71
Study 30518237 — intervention group
Group type: COMPARATOR
Intervention: Unstructured sessions (control)
Number of subjects: 71
Study 30518237 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 71
Study 29453708 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mediated PEERS curriculum
Number of subjects: 34
Study 29453708 — intervention group
Group type: COMPARATOR
Intervention: Traditional PEERS curriculum
Number of subjects: 34
Study 29453708 — intervention group
Group type: EXPERIMENTAL
Intervention: Typically developing peer mentors
Number of subjects: 34
Study 28524097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of vegetables (specifically cruciferous and allium vegetables)
Number of subjects: 1468
Study 28524097 — intervention group
Group type: COMPARATOR
Intervention: Fruits
Number of subjects: 1468